TORONTO (PRWEB) DECEMBER 01, 2021 The FDA has issued two new draft guidance documents on the use and structure of real-world data in regulatory decision-making. While real-world data has been around for many years, in this webinar the xCures speakers will recap the guidance and discuss what this means for the… Read more »
xCures presents the results of their oncology platform at the 2021 SNO Annual Meeting
xCures’ poster at the SNO meeting will show results from their XCELSIOR platform of real-world datasets and clinical outcomes in CNS cancer patients. Today, xCures announced their poster presentation at the 26th Annual Meeting of the Society for Neuro-Oncology, held from the 18th to the 21st of November. The Society… Read more »
xCures hosts xDECIDE webinars
xCures is inviting the oncology community to register for a 25-minute webinar introducing a new clinical decision support tool: xDECIDE. Oncology providers now have access to a toolkit that offers tailored recommendations for treatment options and personalized patient health summaries. To accompany the launch of the platform, Dr. Juneja discusses… Read more »
xCures launches xDECIDE to help oncologists find better treatment options for their patients
Portal helps oncologists find the most recent and relevant therapeutic options for advanced cancer patients so they can focus on treatment evaluation xCures announced today the release of xDECIDE, the latest in the company’s suite of tools to empower oncologists and their teams to identify the most suitable, personalized treatment… Read more »
Jaime Leandro Foundation treats first cancer patient with personalized neoantigen peptide vaccine under expanded access through xCures
First-of-its-kind consortium enables cancer patients to receive anticancer vaccine therapy through compassionate use. The Jaime Leandro Foundation for Therapeutic Cancer Vaccines (JLF) and partners announce the treatment of the first cancer patient with a personalized neoantigen vaccine through a self-pay compassionate use program. JLF is a 501(c)3 non-profit organization whose… Read more »
xCures Partners With Massive Bio to Help Advanced Cancer Patients Find the Right Treatment Options
Collaboration between leading AI-enabled oncology corporations helps provide the best arsenal available for advanced cancer patients NEW YORK–(BUSINESS WIRE)–Today, xCures announced their collaboration with Massive Bio Inc. This partnership ensures that advanced cancer patients and their physicians have access to the best treatment options available. Massive Bio is a leader… Read more »
xCures raises $12.69 million in Series A funding for their AI-powered precision oncology platform
xCures has helped 1000+ advanced cancer patients and their oncologists with treatment options and recently enabled direct access to the platform through xINFORM Oakland, June 23rd, 2021 (PRNewswire) – xCures Inc., the leader in the patient-centric use of artificial intelligence (AI) and predictive modeling, announced today that it has raised… Read more »
xCures provides early access to xINFORM
Today, xCures enabled early access to xINFORM, an A.I.-powered platform for advanced cancer patients to identify personalized treatment options to discuss with their doctors. xINFORM is available at no charge. Patients participate with their data and receive treatment options that combine the leading thinking in precision medicine, patient preferences, and… Read more »
